Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics develops next-generation therapies for severe autoimmune and inflammatory diseases as a clinical-stage biotechnology company. Its updates center on claseprubart, an investigational monoclonal antibody engineered to selectively inhibit the active form of C1s in the classical complement pathway, with programs in chronic inflammatory demyelinating polyneuropathy, generalized myasthenia gravis and multifocal motor neuropathy.
Recurring company news also covers FDA interactions and designations, clinical and preclinical program updates, financial results, public equity offerings, pre-funded warrants, and inducement equity grants under Nasdaq rules. Additional disclosures address DNTH212 and the company’s stated focus on rheumatology indications such as Sjögren’s disease, systemic lupus erythematosus and dermatomyositis.
Dianthus Therapeutics (NASDAQ: DNTH), a clinical-stage biotech company, has successfully closed its upsized public offering, raising approximately $288 million in gross proceeds. The offering included 7,627,879 shares of common stock at $33.00 per share, with underwriters fully exercising their option for an additional 1,140,000 shares.
The company also offered pre-funded warrants for 1,112,121 shares at $32.999 per warrant with a $0.001 exercise price. The proceeds will support Dianthus's preclinical and clinical development activities, working capital, and general corporate purposes. The offering was managed by Jefferies, TD Cowen, Evercore ISI, and Stifel, with LifeSci Capital as lead manager.
Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotech company, has announced the pricing of its upsized public offering at $33.00 per share. The offering consists of 6,487,879 shares of common stock and pre-funded warrants to purchase up to 1,112,121 shares at $32.999 per warrant.
The offering is expected to generate approximately $251 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,140,000 shares. The proceeds will support Dianthus's preclinical and clinical development activities, working capital, and general corporate purposes. The offering is expected to close on September 11, 2025.
Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotech company focused on antibody complement therapeutics, has announced a proposed $150 million underwritten public offering of common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to an additional $22.5 million of common stock.
The offering, led by joint book-running managers Jefferies, TD Cowen, Evercore ISI, and Stifel, will be conducted through a shelf registration statement effective since October 2024. Proceeds will support Dianthus's preclinical and clinical development activities, working capital, and general corporate purposes.
Dianthus Therapeutics (NASDAQ:DNTH) reported positive Phase 2 MaGic trial results for claseprubart (DNTH103) in treating generalized Myasthenia Gravis (gMG). Both 300mg and 600mg doses administered every two weeks showed statistically significant improvements in key efficacy measures.
The trial demonstrated rapid and sustained effectiveness starting from Week 1, with significant improvements in MG-ADL and QMG scores through Week 13. The 300mg dose proved equally effective as 600mg, supporting a convenient single-dose administration via subcutaneous autoinjector every two weeks.
Importantly, claseprubart showed a favorable safety profile with no serious infections, autoimmune symptoms, or drug-related serious adverse events. The company plans to initiate a Phase 3 gMG trial in 2026.
Dianthus Therapeutics (Nasdaq: DNTH) has scheduled a conference call and webcast for September 8, 2025 at 8:00 a.m. EDT to discuss results from their Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG).
The clinical-stage biotechnology company, focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, will host the event with a Q&A session for registered participants. Investors can access the webcast through the company's website, with a replay available afterward.
Dianthus Therapeutics (NASDAQ:DNTH) reported Q2 2025 financial results and business updates, highlighting significant progress in its clinical programs. The company's lead drug candidate claseprubart (DNTH103) is advancing in multiple trials:
The Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) completed enrollment with 65 patients, with top-line results expected in September 2025. The Phase 3 CAPTIVATE trial in CIDP and Phase 2 MoMeNtum trial in MMN are progressing with results anticipated in 2H'26.
Financially, Dianthus reported $309.1 million in cash, providing runway into 2H'27. Q2 net loss was $31.6 million ($0.88 per share), with R&D expenses of $26.3 million and G&A expenses of $8.9 million.
Dianthus Therapeutics (NASDAQ: DNTH), a clinical-stage biotech company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Marino Garcia will lead a fireside chat on June 5, 2025, at 9:55 a.m. EDT in New York City. The presentation will be accessible via webcast in the Investors section of the company's website under "News and Events". Additionally, the company's management will be available for one-on-one meetings with investors during the conference.
Dianthus Therapeutics (NASDAQ: DNTH) has appointed Simon Read, Ph.D. to its Board of Directors, while announcing Lonnie Moulder's transition from the Board. Dr. Read brings over 30 years of biopharmaceutical experience, most recently serving as CEO and founder of Mariana Oncology until its Novartis acquisition in 2024, and previously as CSO of Ra Pharma until its UCB acquisition in 2020.
Dr. Read's extensive background includes R&D leadership roles at major pharmaceutical companies and involvement in developing prominent immunology drugs like Rituxan® and Actemra®. He is currently Chairman of Ethyreal Bio's Board and a Fellow of the Royal Society of Medicine (UK). The company is advancing DNTH103 through clinical trials, with Phase 2 MaGic results expected in September.
Dianthus Therapeutics (DNTH) has completed enrollment for its Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG), exceeding the target with 65 patients enrolled. Top-line results are expected in September 2025. DNTH103 is a monoclonal antibody targeting the classical pathway by inhibiting the active C1s protein, designed for convenient self-administered subcutaneous injection every two weeks.
The trial focuses on patients with acetylcholine receptor antibody-positive gMG, with primary endpoints evaluating safety and tolerability. The U.S. gMG market exceeds 100,000 patients, with 85% having AChR autoantibody-driven disease. DNTH103 is also being evaluated in Phase 3 CAPTIVATE trial for CIDP and Phase 2 MoMeNtum trial for MMN, with results expected in 2H'26.